Basics of Genetics in Obstetric and Gynaecological Practice. by Dr Veronica Arora ( India)

Value of the Information & Strength of the Argument

The presentation delivers substantial clinical value by synthesizing current evidence on prenatal genetic testing. The argumentation is solid: each technological advancement is justified by specific clinical scenarios and supported by landmark peer-reviewed studies. Dr. Arora logically builds from basic genetics to complex testing strategies, consistently linking test selection to the fetal phenotype and the questions at hand. She addresses caveats—such as false reassurance from normal karyotype, the 1-2% VUS rate in CMA, and limitations of exome sequencing—ensuring a balanced and nuanced view. The explanation of NIPT mechanics and its screening-only nature is particularly well-articulated, preventing misuse. The emphasis on trio design, reanalysis, and genetic counseling as integral components of the diagnostic process strengthens the clinical applicability. Overall, the information is precise, evidence-based, and highly useful for practitioners in fetal medicine.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high. The speaker explicitly cites major studies (Wapner et al., NEJM 2012; PAGE and Petrovski studies in Lancet 2019) and guidelines (ACOG, ISPD 2022), grounding her recommendations in robust evidence. She appropriately distinguishes between screening and diagnostic modalities and acknowledges limitations of each test. The title ‘Basics of Genetics’ slightly understates the depth of the content, which includes advanced topics like exome sequencing—but this likely reflects a pedagogical approach. The title accurately indicates the clinical setting (obstetric and gynaecological practice) and the core subject (genetics), making it appropriate. The talk is well-structured, and the speaker’s credentials add credibility. No conflicting sources were mentioned, and the information aligns with current international consensus.

The title accurately reflects the content, covering fundamental genetics concepts applied to obstetric and gynaecological practice, including advanced prenatal testing techniques like CMA and exome sequencing.

9/10

The talk is based on landmark studies (Wapner 2012, PAGE study, Petrovski et al., Lancet 2019) and international guidelines (ACOG, ISPD), with clear explanations of genetic concepts and limitations. The speaker appropriately distinguishes between screening and diagnostic tests and emphasizes the importance of phenotype-driven test selection.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction: posing the question of how far to investigate ultrasound abnormalities, leading to the concept of genomic causes.
• 03:00Genetics refresher: analogy of a city to illustrate layers from karyotype to exome sequencing; resolution levels.
• 05:00Clinically relevant variants: aneuploidy, copy number variants, single-gene mutations; examples like trisomy 21 and 22q11 deletion.
• 07:00Modes of inheritance: autosomal dominant, recessive, X-linked, and de novo; risk percentages.
• 09:00Prenatal testing spectrum: screening vs diagnostic tests; NIPT sensitivity and indications.
• 11:00NIPT mechanism through cell-free DNA; limitations including placental mosaicism and vanishing twin.
• 13:00Karyotype: detection limits (5-10 Mb) and balanced translocations; its role in recurrent pregnancy loss.
• 14:00Microarray: resolution, types (aCGH, SNP), and evidence from Wapner study showing 6% incremental yield in structurally abnormal fetuses.
• 16:00Exome sequencing: when to use (after normal CMA), triad design, and evidence from PAGE/Petrovski studies (10-15% additional yield).
• 18:00Practical workflow: genetic counseling, CVS/amniocentesis, rapid aneuploidy testing, and moving to trio exome; role of reanalysis.
• 20:00Take-home messages: NIPT screens for common aneuploidies, CMA is first tier for structural anomalies, and reanalysis can convert negative to positive.

• Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis (Wapner et al., NEJM 2012) — Landmark study cited as showing 6% incremental yield of CMA over karyotype in fetuses with structural anomalies.
• PAGE Study (Petrovski et al., Lancet 2019) — Prospective study on exome sequencing in fetuses with structural abnormalities, reported ~10% diagnostic yield, higher in selected subgroups.
• ISPD 2022 Recommendations on sequencing — Referenced for when to use exome sequencing and preference for trio design and accredited labs.
• ACOG Guidelines on NIPT — Mentioned that NIPT should be offered to all women regardless of age or ethnicity.
• Sir Dennis Lo's discovery of cell-free fetal DNA — Acknowledged as the basis of NIPT technology.

• ACOG Practice Bulletin on Prenatal Genetic Testing — Supports the recommendation that NIPT be offered to all pregnant women and distinguishes screening from diagnostic testing.
• ISPD 2022 Rapid Fetal Exome Sequencing Guidelines — Aligns with the presentation's guidance on trio exome sequencing for fetuses with structural anomalies and normal CMA.